Navigation Links
Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths

INDIANAPOLIS, May 20 /PRNewswire-FirstCall/ -- Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer.(1)  Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.

"While great strides have been made in treating some cancers over the past decade, others – such as melanoma – continue to be challenging to treat," said John M. Kirkwood, M.D., co-leader of the Melanoma Program of the University of Pittsburgh Cancer Institute.  "Ongoing research is critical if we are to find appropriate treatments for patients who need them most."  

The Phase II study (Abstract #8541) evaluated the use of tasisulam as a second-line treatment in patients with unresectable or metastatic melanoma.  The trial's primary objective was to determine overall response rate and its two secondary objectives were to determine progression-free survival and overall survival.  Of the 68 patients enrolled in the study, eight demonstrated partial response, 24 had stable disease (no progression after two cycles), 25 had progressive disease, and 11 did not have their disease progression completely evaluated.  The median progression-free survival was 2.6 months and the median overall survival was 9.6 months.  

Tasisulam was given in 21-day cycles using a dosing algorithm based on body weight.  The most common grade 3/4 hematologic toxicities were thrombocytopenia (low platelet count), neutropenia (low white blood cell count) and anemia (low red blood cell count).  Non-hematologic toxicities included fatigue, mucositis (inflammation of the mucous membrane) and stomatitis (inflammation of the mucous lining).

Tasisulam was granted orphan drug status for stage 2b-IV melanoma by the U.S. Food and Drug Administration in late 2009.

"Encouraging results from these studies are confirmation that Lilly Oncology is moving in the right direction towards finding innovative solutions for difficult-to-treat cancers," said Richard Gaynor, M.D., vice president, product development and medical affairs at Lilly Oncology. "These studies are in keeping with Lilly's dedication to addressing patient populations that are most in need."

In total, there will be 13 studies presented at ASCO evaluating Lilly pipeline molecules.  Lilly has one of the largest oncology pipelines in the industry, with more than 20 molecules being evaluated for use in a wide range of cancers.

Notes to Editor

About Melanoma

Melanoma is the deadliest form of skin cancer and is frequently attributed to exposure to ultraviolet (UV) radiation.(1)  Although U.S. incidence rates for many cancers have been on the decline, new cases of melanoma have been increasing for the past 30 years.(2)  Recent estimates suggest that more than 68,000 people are diagnosed annually in the U.S. with melanoma.(2)  Melanoma has a pathological staging system, starting at 0 and rising to the severity of stage IV.(3)  The cancer can metastasize, or spread rapidly, moving from the skin to the blood and lymphatic vessels, and then on to the rest of the body.(1)

About Lilly Oncology

For more than four decades, Lilly Oncology, a division of Eli Lilly and Company, has been dedicated to delivering innovative solutions that improve the care of people living with cancer.  Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches.  To learn more about Lilly's commitment to cancer, please visit   

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.


This press release contains forward-looking statements about the potential of tasisulam for the treatment of metastatic melanoma and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(Logo: )

(1) American Academy of Dermatology, "Malignant Melanoma" 2010. Available at: s/sun_malignant.html. Accessed on April 30, 2010.

(2) American Cancer Society, "Detailed Guide: Skin Cancer - Melanoma - What Are the Key Statistics About Melanoma?" March 5, 2010. Available at:  Accessed on April 30, 2010.

(3) American Cancer Society, "Detailed Guide: Skin Cancer – Melanoma: How Is Melanoma Staged?" March 5, 2010. Available at:  Accessed on May 5, 2010.

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations
2. Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
3. Lillys Online, Interactive Health Education Program Receives Two Web Awards
4. Lilly Reports Fourth-Quarter and Full-Year 2009 Results
5. Lilly Confirms Date and Conference Call For Fourth-Quarter and Full-Year 2009 Financial Results Announcement
6. Lilly CEO Stresses Human Element in Driving Medical Innovation
7. Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
8. PDL BioPharma Announces New Licensing Agreement With Eli Lilly
9. Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies
10. Lilly CFO Derica Rice Assumes Expanded Responsibilities, Promoted to Executive Vice President
11. Lilly Declares First-Quarter 2010 Dividend
Post Your Comments:
(Date:10/9/2015)... LAUSANNE , Schweiz, October 9, 2015 Der ... geht an Dr.   Yutaka Kondo und Dr.   ... JCA-Mauvernay Award   2015 " geht an Dr.   ... --> Der " JCA-Mauvernay Award   ... und Dr.   Junko Takita    ™ ...
(Date:10/8/2015)... England and PITTSBURGH , ... ), a leading global pharmaceutical company, will host a ... at 5:00 pm ET to review the value ... (NYSE: PRGO ; TASE) through Mylan,s offer to ... a comprehensive presentation which outlines the compelling proposition for ...
(Date:10/8/2015)... , Oct. 8, 2015  The National Heart, ... $40 million to the Broad Institute of MIT ... of 20,000 individuals, as well as data to ... profiling. Trans-Omics for Precision Medicine ... toward a larger initiative, which will use whole ...
Breaking Medicine Technology:
... Cephalon, Inc. (Nasdaq: CEPH ) today provided notice ... Notes due 2014 (the "2014 Notes") and 2.00 percent ... in respect of the Merger (as defined below) of ... Industries Ltd., an Israeli corporation ("Parent"), the consummation of ...
... The Plasma Protein Therapeutics Association (PPTA) ... temporary and proposed regulations implementing the ... and fails to take into account concerns expressed ... narrow definition of an "orphan drug" disproportionally affects ...
Cached Medicine Technology:
(Date:10/10/2015)... FLA. (PRWEB) , ... October 10, 2015 , ... In ... has been named the Best Place To Work in Jacksonville, amongst medium-sized companies with ... September 27th and was followed up with a celebratory gala on October 1st. ...
(Date:10/9/2015)... Los Angeles, CA (PRWEB) , ... October 09, 2015 , ... ... awareness for breast cancer victims, survivors, and the ongoing effort to find a cure. ... patients another outlet for helping women in need. With their Bra Collection Campaign, Beverly ...
(Date:10/9/2015)... ... ... Smoke alarms can save lives. In fact, according to the National Fire ... home fires in half. As part of Fire Prevention Week, Amica Insurance ... , Half of home fire deaths result from fires reported between 11 p.m. and ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... company, has announced the final product specifications for TRACTUS, the world’s first sterile ... in the United States in response to the FDA’s recent Unique Device Identifier ...
(Date:10/9/2015)... ... October 09, 2015 , ... Cambias Insurance Agency, a family ... initiating a combined charity effort with Animal Rescue New Orleans in an effort ... , Animal Rescue New Orleans is a non-profit organization committed to rescuing and ...
Breaking Medicine News(10 mins):
... so does survival, study finds , MONDAY, Feb. 8 (HealthDay ... with increased risk of death, researchers say. , In a ... again at age 89 in a group of 555 participants ... at 85 and 89 years, and a greater decline in ...
... ... Strash, FACHE, Chief Executive Officer with Oro Valley Hospital, on critical issues facing healthcare ... ... timely communication among different segments of the medical community, Jackson & Coker ( ...
... , CINCINNATI , Feb. 8 Three ... "about right," according to a study of more than 65,000 ... of obesity over the past several years, the number of ... 1999 and 2007," says Nicholas M. Edwards , MD, ...
... triggering bone formation , MONDAY, Feb. 8 (HealthDay News) -- ... osteoporosis in lab mice and rats, a new study has ... gut hinders bone formation. Most current drugs for osteoporosis only ... "New therapies that inhibit the production of serotonin in the ...
... BETHESDA, Md. , Feb. 8 /PRNewswire-Asia/ ... Western healthcare,products and services in the People,s Republic of China , today ... , , Financial Highlights:, -- Revenue in ... over year to $46.5 million;, -- Net ...
... ... McDonald, have formed One2One Partners. The firm creates customized programs that strengthen the relationship ... an engaged workforce and minimize the threat of third-party intervention, regardless of potential legislation ... ...
Cached Medicine News:
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... Eliminate aerosol contamination, which ... in PCR. Hydrophobic, nonwicking ... air can pass through ... in contrast to tips ...
Dnase-free, with an integral filter to protect against carry over and contamination from aerosols...
Medicine Products: